Novel imidazole-based combretastatin A-4 analogues: Evaluation of their in vitro antitumor activity and molecular modeling study of their binding to the colchicine site of tubulin

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 22, 2006, Pages 5757-5762

  Bellina, Fabio ^a   Cauteruccio, Silvia ^a   Monti, Susanna ^b   Rossi, Renzo ^a  

^a UNIVERSITY OF PISA   (Italy)

^b AREA DELLA RICERCA   (Italy)

Author keywords

Antitumor activity; Colchicine; Combretastatin A 4; Cytotoxicity; Imidazoles; Molecular modeling; Tubulin

Indexed keywords

ALPHA TUBULIN; BETA TUBULIN; COLCHICINE; COMBRETASTATIN A4; IMIDAZOLE DERIVATIVE; NSC 613729; NSC 733436; NSC 734602; NSC 734603; NSC 735354; NSC 735355; NSC 736359; NSC 736992; NSC 736993; NSC 736994;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CALCULATION; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG CONFORMATION; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; ELECTRICITY; EVALUATION; EXPERIMENTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR MODEL; TUMOR CELL; TUMOR VASCULARIZATION;

ANTINEOPLASTIC AGENTS; BINDING SITES; CELL LINE, TUMOR; COLCHICINE; HUMANS; IMIDAZOLES; STILBENES; TUBULIN;

EID: 33749258555     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.08.087     Document Type: Article

References (32)

1. Pettit G.R., Singh S.B., Hamel E., Lin C.M., Alberts D.S., and Garcia-Kendall D. Experientia 45 (1989) 209
2. Sackett D.L. Pharmacol. Ther. 59 (1993) 163
3. McGown A.T., and Fox B.W. Cancer Chemother. Pharmacol. 26 (1990) 79
4. Dark G.G., Hill S.A., Prise V.E., Tozer G.M., Pettit G.R., and Chaplin D.J. Cancer Res. 57 (1997) 1829
5. Ravelli R.B.G., Giganti B., Curmi P.A., Jourdain I., Lackar S., Sobel A., and Knossow M. Nature 428 (2004) 198
6. Nguyen T.L., McGrath C., Hermone A.R., Burnett J.C., Zaharevitz D.W., Day B.W., Wipf P., Hamel E., and Gussio R. J. Med. Chem. 48 (2005) 6107
7. Pettit G.R., Rhodes M.R., Herald D.L., Chaplin D.J., Stratford M.R., Hamel E., Pettit R.K., Chapuis J.C., and Oliva D. Anticancer Drug Des. 13 (1998) 981
8. Nam N.H., Kim Y., You Y.-J., Hong D.-H., Ki H.-M., and Ahn B.-Z. Bioorg. Med. Chem. Lett. 11 (2001) 3073
9. For reviews on the chemistry and biology of combretastatin A-4 analogues, see:. Nam N.-H. Curr. Med. Chem. 20 (2003) 558
10. Cirla A., and Mann J. Nat. Prod. Rep. 20 (2003) 558
11. Tron G.C., Pirali T., Sorba G., Pagliai F., Busacca S., and Genazzani A.A. J. Med. Chem. 49 (2006) 3033
12. Wang L., Woods K.W., Li Q., Barr K.J., McCroskey R.W., Hannick S.M., Gherke L., Credo R.B., Hui Y.-H., Marsh K., Warner R., Lee J.Y., Zielnski-Mozng N., Frost D., Rosenberg S.H., and Sham H.L. J. Med. Chem. 45 (2002) 1697
13. Bellina F., Anselmi C., Martina F., and Rossi R. Eur. J. Org. Chem. (2003) 2290
14. Bellina, F.; Falchi, E.; Rossi, R. Atti del Convegno, P8, XVII National Meeting of the Divisione di Chimica Farmaceutica of the Italian Chemical Society, Pisa, Italy, September 6-10, 2004.
15. Bellina, F.; Rossi, R. Abstracts, P9, 26th Winter Meeting of the EORTC-PAMM Group, Arcachon, France, January 26-29, 2005.
16. Bellina F., Cauteruccio S., Mannina L., Rossi R., and Viel S. J. Org. Chem. 70 (2005) 3997
17. Bellina F., Cauteruccio S., Mannina L., Rossi R., and Viel S. Eur. J. Org. Chem. (2006) 693
18. Bellina F., Cauteruccio S., and Rossi R. Eur. J. Org. Chem. (2006) 1379
19. Cushman M., He H.-M., Lin C.M., and Hamel E. J. Med. Chem. 36 (1993) 2817
20. Ohsumi K., Hatanaka T., Fujita K., Nakagawa R., Fukuda Y., Nihei Y., Suga Y., Morinaga Y., Akiyama Y., and Tsuji T. Bioorg. Med. Chem. Lett. 8 (1998) 3153
21. Liou J.-P., Chang J.-Y., Chang C.-W., Chang C.-Y., Mahindroo N., Kuo F.-M., and Hsieh H.-P. J. Med. Chem. 47 (2004) 2897
22. Pettit G.R., Rhodes M.R., Herald D.L., Hamel E., Schmidt J.M., and Pettit R.K. J. Med. Chem. 48 (2005) 4087
23. Ohsumi K., Nakagawa R., Fukuda Y., Hatanaka T., Morinaga Y., Nihei Y., Ohishi K., Suga Y., Akiyama Y., and Tsuji T. J. Med. Chem. 41 (1998) 3022
24. Pérez-Melero C., Maya A.B.S., del Rey B., Caballero E., and Medarde M. Bioorg. Med. Chem. Lett. 14 (2004) 3771
25. Kaffy J., Pontikis R., Carrez D., Croisy A., Monneret C., and Florent J.-C. Bioorg. Med. Chem. 14 (2006) 4067
26. For selected papers on the relationship between tubulin binding properties and selective damage to tumor vasculature, see:. Dark G.G., Hill S.A., Prise V.E., Tozer G.M., Pettit G.R., and Chaplin D.J. Cancer Res. 57 (1997) 1829
27. Tozer G.M., Kanthou C., and Baguley B.C. Nat. Rev. Cancer 5 (2005) 423
28. Maya A.B., Pérez-Melero C., Mateo C., Alonso D., Fernàndez J.J., Gajate C., Mollinedo F., Pelàez R., Caballero E., and Medarde M. J. Med. Chem. 48 (2005) 556
29. Lawrence N.J., Hepworth L.A., Rennison D., McGown A.T., and Hadfield J.A. J. Fluorine Chem. 123 (2003) 101
30. This in vivo test was performed at the Max Delbrück Center for Molecular Medicin in Berlin-Buch. MDA-MB-435 breast cells were chosen since they resulted particularly sensitive in vitro to all new imidazole derivatives (see Supporting Information).
31. Kuntz, I. D. DOCK. University of California, San Francisco, Box 2240, CA 94143-2240. .
32. Case, D. A. et al. AMBER 8. University of California, San Francisco, 2002.